GET THE APP

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemo- therapy (HIPEC), Report of the First Series of Cases in Ecuador | Abstract
Journal of Hepatology and Gastrointestinal disorders

Journal of Hepatology and Gastrointestinal disorders
Open Access

ISSN: 2475-3181

+1-504-608-2390

Abstract

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemo- therapy (HIPEC), Report of the First Series of Cases in Ecuador

Gordillo Villamar Rene*, Medina Donoso Gabriel, Angos Mediavilla Veronica and Gordillo Aldas Daniela

Cyto-Reductive Surgery (CRS) + intraperitoneal hyperthermic chemotherapy (HIPEC) has a survival rate at 10 and 15 years of 63% and 59% respectively in patients with peritoneal neoplasms; severe morbidity is described in older adult patients from 17 to 56% in experienced centers, with a hospital mortality of up to 8%, there is some resistance to its implementation due to complications related to 56%, but the expectation of potential benefit is always attractive.

Published Date: 2020-10-07; Received Date: 2020-07-28

Top